Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

NorthwestBio-App

More Like This

PR Newswire associated0

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

PR Newswire associated0

Northwest Biotherapeutics Announces Expansion of Its Technical Team

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

PR Newswire associated0

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities

PR Newswire associated0

Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference

PR Newswire associated0

Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments

PR Newswire associated0

Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production

PR Newswire associated0

Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property